Severe rebound after cessation of fingolimod treated with ocrelizumabwith coincidental transient aggravation: report of two cases

摘要

Background:Fingolimod (FTY), an oral treatment for patients with relapsing-remitting multiple sclerosis (RRMS), has been associated with a significant rebound of disease activity after cessation of therapy.